Literature DB >> 8431367

Preclinical, phase I and pharmacokinetic studies with the dimethyl phenyltriazene CB10-277.

B J Foster1, D R Newell, J Carmichael, A L Harris, L A Gumbrell, M Jones, P M Goodard, A H Calvert.   

Abstract

Decarbazine is an imidazole dimethyltriazene with reproducible activity in patients with metastatic melanoma. CB10-277 is a phenyl dimethyltriazene which, like dacarbazine, requires metabolic activation to its corresponding monomethyl species for antitumour activity. In preclinical models (human melanoma xenografts and transplantable rodent tumours) CB10-277 showed a similar spectrum and level of activity when compared to dacarbazine. Pharmacokinetic studies were performed with CB10-277 in mice treated i.v. at the LD10 (750 mg m-2) and plasma analysed by HPLC. The parent drug area under the plasma concentration vs time curve (AUC) was 142 mM x minutes. Drug metabolism occurred as evidenced by the HPLC identification of the monomethyl species (AUC = 8 mM x minutes) as well as other metabolites. A Phase I trial using a short infusion with doses repeated every 21 days has been performed. Thirty-six patients received 80 courses over a dose range of 80-6,000 mg m-2. The dose limiting toxicity was nausea and vomiting which occurred in 80% of the evaluable courses > or = 900 mg m-2. The only other common side effect was a flushing or warm sensation, which occurred in over 75% of courses at > or = 1,350 mg m-2. There were no hemodynamic consequences. Responses occurred in patients with melanoma (one complete, two partial, one mixed/11), sarcoma (one mixed/6) and carcinoid (one partial/l). Pharmacokinetics were performed in 46 courses. The CB10-277 AUC increased linearly with dose (r = 0.9203, P < 0.001) up to 700 mM x minutes at 6,000 mg m-2). Evidence of CB10-277 metabolism was observed, as in mice, by detection of the monomethyl species and other metabolites. However, the plasma levels of the monomethyl species in patients (1.8 and 3.7 mM x minutes at 6,000 mg m-2) were less than those predicted from studies in mice. Despite this, antitumour activity in dacarbazine sensitive histologies was observed and additional studies with CB10-277 are recommended.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8431367      PMCID: PMC1968184          DOI: 10.1038/bjc.1993.66

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  25 in total

1.  Mechanism of action and pharmacology studies with DTIC (NSC-45388).

Authors:  T L Loo; G E Housholder; A H Gerulath; P H Saunders; D Farquhar
Journal:  Cancer Treat Rep       Date:  1976-02

2.  Tumour inhibitory triazenes: structural requirements for an active metabolite.

Authors:  T A Connors; P M Goddard; K Merai; W C Ross; D E Wilman
Journal:  Biochem Pharmacol       Date:  1976-02-01       Impact factor: 5.858

3.  Preparation and antitumor activity of 1-aryl-3,3-dimethyltriazene derivatives.

Authors:  T Giraldi; C Nisi; T A Connors; P M Goddard
Journal:  J Med Chem       Date:  1977-06       Impact factor: 7.446

4.  Studies on the mechanism of action of DTIC (NSC-45388).

Authors:  V H Bono
Journal:  Cancer Treat Rep       Date:  1976-02

5.  Studies on the mechanism of action of the tumour inhibitory triazenes.

Authors:  R C Audette; T A Connors; H G Mandel; K Merai; W C Ross
Journal:  Biochem Pharmacol       Date:  1973-08-01       Impact factor: 5.858

6.  Walker carcinosarcoma 256 in study of anticancer agents. I. Method for simultaneous assessment of therapeutic value and toxicity.

Authors:  V M Rosenoer; B C Mitchley; F J Roe; T A Connors
Journal:  Cancer Res       Date:  1966-08       Impact factor: 12.701

Review 7.  DTIC (NSC-45388) in malignant melanoma: a perspective.

Authors:  R L Comis
Journal:  Cancer Treat Rep       Date:  1976-02

8.  Imidazoles. II. 5(or 4)-(Monosubstituted triazeno)imidazole-4(or 5)-carboxamides.

Authors:  Y F Shealy; C A Krauth
Journal:  J Med Chem       Date:  1966-01       Impact factor: 7.446

9.  Combination chemotherapy with DTIC (NSC-45388) in advanced malignant melanoma, soft tissue sarcomas, and Hodgkin's disease.

Authors:  G Beretta; G Bonadonna; E Bajetta; G Tancini; M De Lena; A Azzarelli; U Veronesi
Journal:  Cancer Treat Rep       Date:  1976-02

10.  Antitumor 1-(X-aryl)-3,3-dialkyltriazenes. 1. Quantitative structure-activity relationships vs. L1210 leukemia in mice.

Authors:  G J Hatheway; C Hansch; K H Kim; S R Milstein; C L Schmidt; R N Smith; F R Quinn
Journal:  J Med Chem       Date:  1978-06       Impact factor: 7.446

View more
  3 in total

1.  Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics.

Authors:  D R Newell; S S Burtles; B W Fox; D I Jodrell; T A Connors
Journal:  Br J Cancer       Date:  1999-11       Impact factor: 7.640

2.  Novel Immune Modulators Enhance Caenorhabditis elegans Resistance to Multiple Pathogens.

Authors:  Nicholas A Hummell; Alexey V Revtovich; Natalia V Kirienko
Journal:  mSphere       Date:  2021-01-06       Impact factor: 4.389

3.  A Cancer Research Campaign (CRC) phase II trial of CB10-277 given by 24 hour infusion for malignant melanoma.

Authors:  N M Bleehen; A H Calvert; S M Lee; P Harper; S B Kaye; I Judson; M Brampton
Journal:  Br J Cancer       Date:  1994-10       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.